O
OptiNose
A publicly traded, global specialty pharmaceutical company focused on serving the needs of patients cared for by ENT and Allergy specialists
About OptiNose
Optinose is a specialty pharmaceutical company dedicated to developing and commercializing innovative products for patients with diseases managed by ear, nose, and throat (ENT) and allergy specialists. The company operates in the healthcare sector, focusing on improving the quality of life for patients through advanced medical solutions. Optinose serves a niche market of ENT and allergy specialists, providing them with cutting-edge treatments that aim to become the standard of care in their fields.
The business model of Optinose revolves around research and development, followed by the commercialization of its pharmaceutical products. Revenue is generated through the sale of these specialized medications to healthcare providers and institutions. The company invests heavily in clinical trials and regulatory approvals to ensure the efficacy and safety of its products.
Optinose's market includes healthcare providers, particularly those specializing in ENT and allergy treatments. By focusing on this specific segment, the company aims to address unmet medical needs and offer solutions that significantly improve patient outcomes.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2002
- Headquarters
- Yardley, United States
- Listing
- IPO 2017
- Sector
- Biotech & Life Sciences
- Power Law
- Colt$25–100M revenue
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later7 investors entered at this stage
- OHOxygen House
Avista Healthcare Partners- WVWFD Ventures
Entrepreneurs Fund
Fidelity Investments
D.E. Shaw Group- NMNantahala Capital Management
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Market sentiment
An AI-synthesised read of the highest-engagement posts about OptiNose on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See OptiNose on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.